| Summary: | Evidence showing the role of long non-coding RNAs (lncRNAs) in leukemogenesis have emerged in the last decade. It has been proposed that these genes can be used as diagnosis and/or prognosis biomarkers in childhood acute lymphoblastic leukemia (ALL). To know if lncRNAs are associated with early relapse and early mortality, a microarray-based gene expression analysis in children with B-lineage ALL (B-ALL) was conducted. Cox regression analyses were performed. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated. <i>LINC00152</i> and <i>LINC01013</i> were among the most differentially expressed genes in patients with early relapse and early mortality. For <i>LINC00152</i> high expression, the risks of relapse and death were HR: 4.16 (95% CI: 1.46−11.86) and HR: 1.99 (95% CI: 0.66−6.02), respectively; for <i>LINC01013</i> low expression, the risks of relapse and death were HR: 3.03 (95% CI: 1.14−8.05) and HR: 6.87 (95% CI: 1.50−31.48), respectively. These results were adjusted by NCI risk criteria and chemotherapy regimen. The lncRNA−mRNA co-expression analysis showed that <i>LINC00152</i> potentially regulates genes involved in cell substrate adhesion and peptidyl−tyrosine autophosphorylation biological processes. The results of the present study point out that <i>LINC00152</i> could be a potential biomarker of relapse in children with B-ALL.
|
|---|
